Emtricitabine

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 26.10.2024

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic. Nucleoside inhibitor of HIV reverse transcriptase.

Half-lifeThis section has been translated automatically.

39 hours.

IndicationThis section has been translated automatically.

Antiretroviral combination therapy for the treatment of HIV-1 infection in treatment-naive or previously treated patients > 3 months. Also approved as a combination preparation with tenofovir disoproxil(TDF) for HIV-PrEP.

Pregnancy/nursing periodThis section has been translated automatically.

Strict indication during pregnancy (insufficient data available). Contraindicated during breastfeeding or during therapy weaning (it is not known whether the substance passes into breast milk).

Dosage and method of useThis section has been translated automatically.

Adults/youth/children > 4 months and > 33 kg KG: once/day 200 mg p.o.

Undesirable effectsThis section has been translated automatically.

Frequent headaches, gastrointestinal symptoms such as nausea, vomiting. Occasionally neutropenia, anemia, hypertriglyceridemia, hyperglycemia.

PreparationsThis section has been translated automatically.

Emtriva

Authors

Last updated on: 26.10.2024

Author: Prof. Dr. med. Peter Altmeyer